Dope Magazine Features Medical Marijuana, Inc. Subsidiary HempMeds® Mexico In Historic ‘Look At America’s Reverse-Cannabis Pipeline’

Article Also Details Company’s Pioneering Role in Latin America’s Burgeoning Cannabis Market

SAN DIEGO, March 8, 2017 — Medical Marijuana, Inc. (OTC:MJNA) announced today that its subsidiary HempMeds® Mexico, the first company to receive government import permits for the cannabidiol (CBD) oil product RSHO-X™ via the Mexican Health Department COFEPRIS was featured in a Dope Magazine article highlighting the Company’s role in fueling less restrictive medical cannabis programs in Mexico.

The March 3, 2017, article titled “Mexico’s Evolving Stance on Marijuana” discusses how the plight of one young Mexican girl led Mexico’s government to allow Medical Marijuana, Inc.’s hemp-based CBD oil RSHO-X™ across its border. The article also describes how Medical Marijuana, Inc. has been instrumental in the acceptance and legalization of cannabis products across other Latin American countries including Brazil, Paraguay and Chile – with its exports of Real Scientific Hemp Oil™ (RSHO™) and the THC-free alternative, RSHO-X™.

“This recent article in Dope Magazine shows how the world is opening their eyes to the many therapeutic benefits of medical cannabis,” said Chief Executive Officer of Medical Marijuana, Inc. Dr. Stuart Titus. “We are proud to be recognized as the only Company with legal cannabis-based products allowed to be imported into Mexico. As the tide of opinion regarding medical cannabis continues to change in Mexico and Latin America, we will continue to work alongside lawmakers, doctors and patients in effort to bring access to those who need it most.”

Recent clinical data from epilepsy studies performed in Mexico by Dr’s. Carlos Aguirre and Saul Garza Morales show the beneficial aspects of botanical CBD vs the pharmaceutical version.  Improvements in overall seizure reduction were shown to significantly favor the botanical CBD version over the pharma developed alternative – all with zero side effects. The pharma product has been experiencing a 30% adverse side effect detriment to where many families and children have had to discontinue with the pharma-based studies.

The Dope Magazine article also states that HempMeds® now treats “upwards of 1,500 families with epileptic children in Brazil alone,” as acceptance of CBD as a legitimate medical treatment for a growing number of illnesses continues to grow.

About HempMeds® Mexico

HempMeds®Mexico is a Mexico-based company that made history by being the first company to receive a COFEPRIS federal government import permit for the cannabis product RSHO-X™ for a medical indication. HempMeds® Mexico plans to work directly with the Mexican government to safely and legally provide access to CBD hemp oil products. For more information, please review the company’s website at:

About Medical Marijuana, Inc.

Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit

To see Medical Marijuana, Inc.’s video statement, click here. Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.


This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties. The statements in this press release have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act. The Company does sell and distribute hemp-based products.


Public Relations Contact:

Andrew Hard

Chief Executive Officer

CMW Media

P. 888-829- 0070

[email protected]